Next-generation biosensors
Elegant, scalable biosensors for the point-of-care and beyond
BioSensor Group Ltd has developed a next-generation electrochemical biosensor platform designed for rapid, affordable, and multiplex testing. Our smartphone-enabled approach aims to simplify complex diagnostics and sensing across human health, veterinary, agriculture, and environmental monitoring—without compromising on quality or usability.
More about our technology
LifeSADX (Pty) Ltd, now a wholly owned subsidiary of BioSensor Group Ltd (Seattle, USA) announced Phase 1 clinical data demonstrating that its patented smartphone-integrated electrochemical biosensor platform can deliver HIV-1 viral load results in just 0.1 seconds.
The system is able to detect as low as 45 RNA copies/mL with >99% sensitivity and specificity, all without amplification.
KEY ADVANTAGES
Detects as low as 45 RNA copies/ml without amplification
Sensitivity down to 1-5 fg/ml
Truly mobile – smartphone plus potentiostat
Shelf life of 3 years at 60°C, no cold chain required
Quantitative results in seconds
Compatible with continuous monitoring patches
Unlimited multiplexing capability per sensor strip
Cost-effective and scalable
Patented
Validated across multiple prototypes
Typical Biosensor Workflow
Example: HIV-1 Viral Load (VL)
Step 1:
Connect potentiostat to the smartphone, and insert a VL sensor test strip in the potentiostat as indicated
Step 2:
Lance finger to produce a small drop of blood (i.e. 20 ul)
Step 3:
When the sensor strip touches the blood, the correct volume of blood will be collected
Step 5:
The test result is displayed in as little as 0.13 seconds
Step 4:
The app automatically displays the start screen - press Start to commence testing, and Cancel to discontinue
Collaboration
If you have developed any immunological or molecular detection agents (e.g., antibodies, antigens, aptamers, enzymes, oligos) or other biorecognition elements that are well-characterized but not yet fully commercialized
If you have a prototype diagnostic assay, sensor, or detection method (even at proof-of-concept) that has potential for real-world application but has “remained in the lab”
If you have promising graduate research outcomes that are well-validated but lack a commercial pathway
Our biosensor platform can help accelerate the translation of R&D products to market
Our expertise spans optimization, integration into biosensor devices, scaling, regulatory strategy, commercialization, and licensing arrangements.
Applicable across numerous sectors:
Human Health
Infectious Diseases (including zoonoses)
Neglected Tropical Diseases
Maternal and Infant Health
Agriculture
Plant Disease Detection
Plant Hormone Detection
Veterinary
Early Disease Diagnosis in Livestock
Zoonotic Disease Detection (Animal-to-Human Transmission)
Marine Biology
Pathogen and Disease Detection in Aquaculture
Monitoring Harmful Algal Blooms (HABs)
Military and Defense
Biothreat and Biowarfare Agent Detection
Soldier Health and Performance Monitoring
Field Diagnostics for Military Medicine
About Us
BioSensor Group Ltd has acquired LifeSADX (Pty) Ltd as a wholly-owned subsidiary.
The acquisition of LifeSADX (Pty) Ltd by BioSensor Group Ltd reflects a deliberate global strategy:
BioSensor Group Ltd will hold the intellectual property and manage international contractual obligations.
LifeSADX (Cape Town) will serve as the operational hub for R&D, manufacturing, and commercialization, with a special focus on collaborations with African universities and research groups.
This partnership strengthens our ability to build bridges — between African innovation and global impact. Our platform is not only validated, but ready to accelerate commercialisation through partnerships across research, healthcare, and industry.
About BioSensor Group Ltd
BioSensor Group Ltd, headquartered in Seattle, USA, is the parent company and global IP holder of the biosensor platform. BioSensor Group is committed to advancing disruptive diagnostic technologies with international partners, targeting both high-burden disease areas and next-generation health challenges.
About LifeSADX (Pty) Ltd
LifeSADX (Pty) Ltd is a biotechnology company based in Cape Town, South Africa, developing next-generation electrochemical biosensors for point-of-care diagnostics. LifeSADX is expanding the technology into broader applications: human health (TB, HPV, malaria, neglected tropical diseases, maternal health), veterinary and agricultural diagnostics (horticulture, food safety, animal health), environmental monitoring (marine biology), and pandemic preparedness.
The Team
Mr. Louis Roux (Chief Executive Officer)
Louis is a founding member of both LifeSADX (Pty) Ltd and BioSensor Group Ltd. Under his leaderhipship, numerous awards and grants have been received, including two consecutive Gates Grand Challenge awards for product development and commercialization. With over 15 years of experience in IVD manufacturing and commercialization, he has successfully secured procurement contracts with prominent organizations such as Médecins Sans Frontières (MSF), the Centres for Disease Control and Prevention (CDC, USA), the South African Government, and various private entities across the world. He also holds an appointment as a Diagnostic Expert with the European Commission in Brussels (EDCTP Programme). He holds BSc, BSc (Hons), and MSc degrees from Pretoria University.
Dr. Takunda Gwanzura (Chief Scientific Officer)
Dr. Takunda Gwanzura was born in Harare, Zimbabwe in 1992. He is the inventor of a electrochemical biosensor platform (PCT patented) and a plant-nanoparticle formulation for treating breast- and colorectal cancer (PCT patented). His research interests include biosensor development and implementation across all industries, development of nanotechnologies that can be applied to diagnostics, drug delivery systems and medicinal plants. Dr. Gwanzura has over 10 years practical experience in these fields and is the head of R&D at both BioSensor Group Ltd and LifeSADX in Cape Town. Qualifications: BSc, MSc (Chemistry), PhD (Electronic Engineering).
Mr. Ralph Schneideman (Vice President of Corporate Development)
Ralph’s career spans twenty-six years of qualified international healthcare experience in creating, building, and redeveloping commercialisation initiatives within global private, NGO, public service, and national government initiatives. Qualified experience within multicultural, legal, and application environments for commercial healthcare, industrial, and agriculture projects. Master of International Management degree from the American Graduate School of Global Management and a BA in Political Science from the University of California Los Angeles.
Contact Us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!